Laromestrocel vs RB-ADSC
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Alzheimer's Disease
Shared mechanism: Mesenchymal stem cell therapy · full Alzheimer's Disease pipeline
Laromestrocel · Lomecel-B
Developed by Longeveron (NASDAQ: LGVN)
NCT05233774 · Phase 2 · completed
This trial was randomized, blinded, and placebo-controlled, but it enrolled only 50 patients and was designed primarily to test safety rather than a clinical outcome; cognitive measures were assessed only as secondary endpoints. The safety objective was met, but the small size and safety-focused design mean this trial does not by itself demonstrate a clinical benefit. Its registered primary outcome on ClinicalTrials.gov is "Primary Endpoint 1: Safety - SAEs and AEs" (with 1 other safety or dose-finding measure). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
Reported efficacy
Primary Endpoint 1: Safety - SAEs and AEs (41 weeks); Primary Endpoint 2: Safety - Imaging (41 weeks): Primary safety endpoint (SAEs/AEs through 41 weeks): no infusion-related reactions, no ARIA, no deaths in any group; 1 SAE within 30 days post-infusion in each of the three Lomecel-B dose groups (3 total) versus 0 SAEs in the placebo group. (not_applicable)
Result source: NCT05233774
RB-ADSC
Developed by Regeneration Biomedical, Inc.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: September 2028 · NCT07373067 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Alzheimer's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Laromestrocel | RB-ADSC |
|---|---|---|
| CDR-SB, change | —Not reported | —Not reported |
| ADAS-Cog11, change | —Not reported | —Not reported |
| ADCS-ADL, change | —Not reported | —Not reported |
| MMSE, change | —Not reported | —Not reported |
| Amyloid PET, change (centiloids) | —Not reported | —Not reported |
CDR-SB, change
- Laromestrocel
- —Not reported
- RB-ADSC
- —Not reported
ADAS-Cog11, change
- Laromestrocel
- —Not reported
- RB-ADSC
- —Not reported
ADCS-ADL, change
- Laromestrocel
- —Not reported
- RB-ADSC
- —Not reported
MMSE, change
- Laromestrocel
- —Not reported
- RB-ADSC
- —Not reported
Amyloid PET, change (centiloids)
- Laromestrocel
- —Not reported
- RB-ADSC
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Laromestrocel: no structured comparison results are available for Alzheimer's Disease.
RB-ADSC: no structured comparison results are available for Alzheimer's Disease.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Laromestrocel's landscape · RB-ADSC's landscape